EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

George J Kontoghiorghes iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242316749 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von George J Kontoghiorghes. Beteiligte Einrichtung: Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus. Hauptthemen laut MEDLINE: Iron Overload, beta-Thalassemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 321 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postgraduate Research Institute of Science, Technology, Environment and Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The design of clinical protocols and the selection of drugs with appropriate posology are critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be designed in all diseases including for millions of patients affected by excess iron deposition (EID) toxicity based on personalised medicine parameters, as well as many variations and limitations. EID is an adverse prognostic factor for all diseases and especially for millions of chronically red-blood-cell-transfused patients. Differences in iron chelation therapy posology cause disappointing results in neurodegenerative diseases at low doses, but lifesaving outcomes in thalassemia major (TM) when using higher doses. In particular, the transformation of TM from a fatal to a chronic disease has been achieved using effective doses of oral deferiprone (L1), which improved compliance and cleared excess toxic iron from the heart associated with increased mortality in TM. Furthermore, effective L1 and L1/deferoxamine combination posology resulted in the complete elimination of EID and the maintenance of normal iron store levels in TM. The selection of effective chelation protocols has been monitored by MRI T2* diagnosis for EID levels in different organs. Millions of other iron-loaded patients with sickle cell anemia, myelodysplasia and haemopoietic stem cell transplantation, or non-iron-loaded categories with EID in different organs could also benefit from such chelation therapy advances. Drawbacks of chelation therapy include drug toxicity in some patients and also the wide use of suboptimal chelation protocols, resulting in ineffective therapies. Drug metabolic effects, and interactions with other metals, drugs and dietary molecules also affected iron chelation therapy. Drug selection and the identification of effective or optimal dose protocols are essential for positive therapeutic outcomes in the use of chelating drugs in TM and other iron-loaded and non-iron-loaded conditions, as well as general iron toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iron Overloadbeta-ThalassemiaHumansDeferiproneDeferoxaminePyridonesIron Chelating AgentsChelation TherapyIronDrug Therapy, Combination

Stichwörter der Autor:innen

aspirindrug efficacydrug toxicityiron chelation therapyiron overloadneurodegenerative diseasesoptimal dose protocolspharmacologythalassemia

Substanzen

DeferiproneDeferoxaminePyridonesIron Chelating AgentsIron

Autor:innen und Institutionen

  • Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus.

ORCID-Profile: George J Kontoghiorghes

Förderung

  • Postgraduate Research Institute of Science, Technology, Environment and Medicine

Zitieren

APA

Kontoghiorghes, G. J. (2023). Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316749

Vancouver

Kontoghiorghes GJ. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316749

BibTeX
@article{Kontoghiorghes2023,
  author = {Kontoghiorghes, George J},
  title = {Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242316749}
}
Kostenlos starten →